3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
8
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
593
Cyclophosphamide
539
Magnetic Resonance Spectroscopy
527
Radiotherapy
506
Specimen Handling
504
Nivolumab
406
Cisplatin
370
Carboplatin
360
Biopsy
306
Blood Specimen Collection
296
Radiosurgery
284
Paclitaxel
276
Surveys and Questionnaires
269
Standard of Care
267
Gemcitabine
266
fludarabine
261
Dexamethasone
258
Drug Therapy
256
Bevacizumab
248
venetoclax
247
Oxaliplatin
206
Rituximab
197
Capecitabine
194
Radiation
190
Fluorouracil
186
Ipilimumab
183
durvalumab
181
Doxorubicin
174
atezolizumab
172
Etoposide
171
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
brigimadlin
×
1 year
×
Clear all
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn